ValiRx PLC Director Disclosure (1916M)

TIDMVAL

RNS Number : 1916M

ValiRx PLC

19 January 2021

19 January 2021

("ValiRx", the "Company" or the "Group")

Director Disclosure

London, UK - ValiRx plc ("ValiRx", AIM:VAL), a clinical stage drug development company, announces that Martin Lampshire, Non-Executive Director of the Company, has advised ValiRx that, on 21 December 2020, the creditors of Global Resources Investment Trust PLC, of which he is a director, approved a Company Voluntary Arrangement.

This announcement is made in accordance with Rule 17 and schedule 2, paragraph (g) of the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.

Ends

For further information please contact:

 
 ValiRx plc                                        Tel: [phone] 
                                                    www.valirx.com 
 Suzanne Dilly, CEO                                [e-mail] 
  Cairn Financial Advisers LLP (Nominated           Tel: [phone] 
   Adviser)                                          0880 
   Liam Murray / Jo Turner / Ludovico Lazzaretti 
  Peterhouse Capital Limited (Sole Broker)          Tel: [phone] 
   Duncan Vasey / Lucy Williams / Eran Zucker        0930 
  Optimum Strategic Communications                  Tel: [phone] 
   Supriya Mathur/ Shabnam Bashir                    3040 
                                                     [e-mail] 
 

About ValiRx plc

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCEAFFNFDLFEFA

(END) Dow Jones Newswires

January 19, 2021 06:36 ET (11:36 GMT)